Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Acute Respiratory Distress Syndrome Clear all
Completed Phase 2 Interventional Results available

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
Interventions
Mesenchymal stromal cells, Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Withdrawn Phase 2 Interventional

Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS

NCT03376854
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Sars-CoV2
Interventions
Hypothermia, Neuromuscular Blocking Agents, Standard of Care
Device · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729606
View directory record Official record
Conditions
Covid19
Interventions
Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

NCT04388826
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Veru-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jul 21, 2026, 6:08 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Little Lungs Study

NCT06855043
View directory record Official record
Conditions
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions
Calfactant, Budesonide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Days to 14 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

NCT04308668
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting No phase listed Observational

Ventilatory Parameters in Predicting Outcomes in ARDS Patients

NCT06400095
View directory record Official record
Conditions
ARDS, Mechanical Power
Interventions
Poccl, Time constant, driving pressure
Diagnostic Test
Lead sponsor
CentraCare
Other
Eligibility
19 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Saint Cloud, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting Phase 2 Interventional

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

NCT05947955
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Infections
Interventions
Rhu-pGSN, normal saline
Drug
Lead sponsor
BioAegis Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Not applicable Interventional Results available

Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms

NCT04382391
View directory record Official record
Conditions
COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult, ARDS, Human, SARS (Severe Acute Respiratory Syndrome)
Interventions
gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jul 21, 2026, 6:08 PM EDT
Completed No phase listed Observational

Ketamine Infusion as Sedative Analgesic in Severe ARDS

NCT04818827
View directory record Official record
Conditions
Intensive Care Unit Syndrome, Mechanical Ventilation Complication, Sedatives and Hypnotics Causing Adverse Effects in Therapeutic Use, Delirium
Interventions
Not listed
Lead sponsor
Interfaith Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

NCT04582201
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
agenT-797
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Santa Monica, California • Louisville, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Completed No phase listed Observational

Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure

NCT03225807
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency, Respiratory Distress Syndrome, Shock Lung, Severe Acute Respiratory Syndrome
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure

NCT01739933
View directory record Official record
Conditions
Sepsis, Delirium, Impaired Cognition
Interventions
Dexmedetomidine, Propofol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
11
States / cities
San Francisco, California • Baton Rouge, Louisiana • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Jul 21, 2026, 6:08 PM EDT
Not yet recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 4 Interventional Results available

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

NCT04340557
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
Losartan
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

NCT04369469
View directory record Official record
Conditions
COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
Interventions
Ravulizumab, BSC
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

NCT04750278
View directory record Official record
Conditions
Severe to Critical COVID 19 With Associated ARDS
Interventions
FP-025 100 mg, FP-025 300 mg, Placebo
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

NCT04842747
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
VERU-111
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Chula Vista, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

NCT04412668
View directory record Official record
Conditions
SARS-CoV-2 (COVID-19) Severe Pneumonia
Interventions
Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo
Drug
Lead sponsor
aTyr Pharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
8
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 21, 2026, 6:08 PM EDT
Active, not recruiting Phase 2 Interventional

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

NCT04488081
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine
Drug · Biological
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
36
States / cities
Birmingham, Alabama • Davis, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

NCT00016523
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Respiratory Distress Syndrome (RDS), Sepsis, Pneumonia, Hypertension, Pulmonary
Interventions
Inhaled nitric oxide, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 120 Hours
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Jul 21, 2026, 6:08 PM EDT